凯发天生赢家一触即发首页

CAR-M cells

CAR-M cells

CAR-M cell therapy involves transferring edited, specific CAR genes into macrophages, enabling them to bind to the surface of tumor cells through specific antigen identification and subsequently activate macrophage activity targeting tumor cells. Genetically engineered CAR-M cells can not only target and phagocytose tumor cells but also alter the tumor microenvironment by secreting pro-inflammatory cytokines and present tumor antigens to T cells, activating the T cell immune response against the tumor. The advent of CAR-M has opened up new possibilities for treating solid tumors: modifying human macrophages with specific CARs to enhance phagocytic activity and macrophage antigen presentation against tumors. Shenzhen Cell Valley will collaborate with clients to explore the most suitable CAR structures, exogenous genes, and transduction conditions for macrophages, contributing to CAR-M research and development.
Description

Overview

•  CAR-M cell therapy involves transferring edited, specific CAR genes into macrophages, enabling them to bind to the surface of tumor cells through specific antigen identification and subsequently activate macrophage activity targeting tumor cells. Genetically engineered CAR-M cells can not only target and phagocytose tumor cells but also alter the tumor microenvironment by secreting pro-inflammatory cytokines and present tumor antigens to T cells, activating the T cell immune response against the tumor. The advent of CAR-M has opened up new possibilities for treating solid tumors: modifying human macrophages with specific CARs to enhance phagocytic activity and macrophage antigen presentation against tumors.
•  Shenzhen Cell Valleywill collaborate with clients to explore the most suitable CAR structures, exogenous genes, and transduction conditions for macrophages, contributing to CAR-M research and development.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact：Ms. Lai

Email：laijiaqi@aicaocy.com

Address：No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Bottom Navigation
Shenzhen Cell Valley Biopharmaceutical Co., Ltd.​​ is a comprehensive one-stop outsourcing service provider in China focused on the cell and gene therapy industry. It is also one of the first CRO/CDMO companies in the country to possess GMP industrial production capabilities for clinical-grade retroviral vectors . The company is a major public technical service platform construction project for CRO/CDMO in Shenzhen and is included among the city's latest announced "20+8" strategic emerging industry projects.Shenzhen Cell Valley has the capability for standardized and industrialized production of GMP-grade cell products such as CAR-T cells. Its primary production lines include those for various cell products like CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T. Additionally, the company operates production lines for various viral vectors, including RVV, LVV, non-viral vectors, and AAV, as well as for cellular raw materials used in producing therapeutics such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses, and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书：(粤)-非经营性-2022-0426  Technical Support：YouDian Software